Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
08 mars 2018 18h00 HE | Xeris Pharmaceuticals, Inc.
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) -- CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
xeris_logo-1.png
Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
04 févr. 2016 10h22 HE | Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...